BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gómez M. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clin Microbiol Infect 2016;22:839-45. [PMID: 27677698 DOI: 10.1016/j.cmi.2016.09.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Hussein KH, Park KM, Yu L, Kwak HH, Woo HM. Decellularized hepatic extracellular matrix hydrogel attenuates hepatic stellate cell activation and liver fibrosis. Mater Sci Eng C Mater Biol Appl 2020;116:111160. [PMID: 32806289 DOI: 10.1016/j.msec.2020.111160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Crawford JM, Bioulac-sage P, Hytiroglou P. Structure, Function, and Responses to Injury. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 1-87. [DOI: 10.1016/b978-0-7020-6697-9.00001-7] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Jiménez-Sousa MÁ, Gómez-Moreno AZ, Pineda-Tenor D, Brochado-Kith O, Sánchez-Ruano JJ, Artaza-Varasa T, Gómez-Sanz A, Fernández-Rodríguez A, Resino S. The Myeloid-Epithelial-Reproductive Tyrosine Kinase (MERTK) rs4374383 Polymorphism Predicts Progression of Liver Fibrosis in Hepatitis C Virus-Infected Patients: A Longitudinal Study. J Clin Med 2018;7:E473. [PMID: 30477195 DOI: 10.3390/jcm7120473] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
4 Debnath P, Nair S, Rathi P, Junare P, Jain S, Chandnani S, Singh A, Contractor Q. Serum biomarkers as an alternative to vibration controlled transient elastography in liver fibrosis staging in chronic hepatitis C. Acta Gastroenterol Belg 2021;84:43-50. [PMID: 33639692 DOI: 10.51821/84.1.776] [Reference Citation Analysis]
5 Ridziauskas M, Zablockienė B, Jančorienė L, Samuilis A, Zablockis R, Jackevičiūtė A. Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs. Medicina (Kaunas) 2021;57:210. [PMID: 33652777 DOI: 10.3390/medicina57030210] [Reference Citation Analysis]
6 Ippolito G, Antonelli G. Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals. Clin Microbiol Infect 2016;22:824-5. [PMID: 27863749 DOI: 10.1016/j.cmi.2016.10.016] [Reference Citation Analysis]
7 Grewal T, Buechler C. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. IJMS 2022;23:1070. [DOI: 10.3390/ijms23031070] [Reference Citation Analysis]
8 Huang W, Ye D, He W, He X, Shi X, Gao Y. Activated but impaired IFN-γ production of mucosal-associated invariant T cells in patients with hepatocellular carcinoma. J Immunother Cancer 2021;9:e003685. [PMID: 34789552 DOI: 10.1136/jitc-2021-003685] [Reference Citation Analysis]
9 Garcia-Broncano P, Medrano LM, Berenguer J, Brochado-Kith O, González-García J, Jiménez-Sousa MÁ, Quereda C, Sanz J, Téllez MJ, Díaz L, JIménez JL, Resino S; GESIDA 3603b Study Group. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study. J Infect 2020;80:99-110. [PMID: 31585189 DOI: 10.1016/j.jinf.2019.09.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Resino S, Fernández-Rodríguez A, Pineda-Tenor D, Gómez-Moreno AZ, Sánchez-Ruano JJ, Artaza-Varasa T, Muñoz-Gómez MJ, Virseda-Berdices A, Martín-Vicente M, Martínez I, Jiménez-Sousa MA. TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients. J Clin Med 2021;10:483. [PMID: 33525598 DOI: 10.3390/jcm10030483] [Reference Citation Analysis]
11 Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. J Hepatol 2018;68:940-8. [PMID: 29288753 DOI: 10.1016/j.jhep.2017.12.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
12 Whiteley D, Speakman E, Elliott L, Davidson K, Hamilton E, Jarvis H, Quinn M, Flowers P. Provider-related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis. J Viral Hepat 2021;28:528-37. [PMID: 33215781 DOI: 10.1111/jvh.13443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease 2019;51:183-9. [DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Tak KH, Yu GI, Lee MY, Shin DH. Association Between Polymorphisms of Interleukin 1 Family Genes and Hepatocellular Carcinoma. Med Sci Monit 2018;24:3488-95. [PMID: 29802240 DOI: 10.12659/MSM.907524] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection. J Gastroenterol 2018;53:1089-97. [PMID: 29500489 DOI: 10.1007/s00535-018-1445-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Valiakou V, Eliadis P, Karamichali E, Tsitsilonis O, Koskinas J, Georgopoulou U, Foka P. Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment. Int J Mol Sci 2021;22:7961. [PMID: 34360721 DOI: 10.3390/ijms22157961] [Reference Citation Analysis]
17 Attallah AM, Omran D, Abdelrazek MA, Hassany M, Saif S, Farid A, El Essawey R, Ghaffar MA, Aabdelghany M, Yosry A. IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy. J Genet Eng Biotechnol 2021;19:150. [PMID: 34623551 DOI: 10.1186/s43141-021-00250-y] [Reference Citation Analysis]
18 Mendes LC, Stucchi RS, Vigani AG. Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies. Hepat Med. 2018;10:13-22. [PMID: 29662329 DOI: 10.2147/hmer.s125234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
19 Aldámiz-Echevarría T, Resino S, Bellón JM, Jiménez-Sousa MA, Miralles P, Medrano LM, Carrero A, Díez C, Pérez-Latorre L, Fanciulli C, Garcia-Broncano P, Berenguer J. European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study. J Transl Med 2019;17:244. [PMID: 31349790 DOI: 10.1186/s12967-019-1997-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Sofias AM, De Lorenzi F, Peña Q, Azadkhah Shalmani A, Vucur M, Wang JW, Kiessling F, Shi Y, Consolino L, Storm G, Lammers T. Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. Adv Drug Deliv Rev 2021;175:113831. [PMID: 34139255 DOI: 10.1016/j.addr.2021.113831] [Reference Citation Analysis]
21 Jiménez-Sousa MÁ, Gómez-Moreno AZ, Pineda-Tenor D, Sánchez-Ruano JJ, Fernández-Rodríguez A, Artaza-Varasa T, Gómez-Sanz A, Martín-Vicente M, Vázquez-Morón S, Resino S. PNPLA3 rs738409 polymorphism is associated with liver fibrosis progression in patients with chronic hepatitis C: A repeated measures study. J Clin Virol 2018;103:71-4. [PMID: 29674183 DOI: 10.1016/j.jcv.2018.04.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
22 Jiménez-Sousa MÁ, Gómez-Moreno AZ, Pineda-Tenor D, Sánchez-Ruano JJ, Artaza-Varasa T, Martin-Vicente M, Fernández-Rodríguez A, Martínez I, Resino S. Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study. Biomolecules 2019;9:E143. [PMID: 30970632 DOI: 10.3390/biom9040143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Pineda-Tenor D, Gómez-Moreno AZ, Sánchez-Ruano JJ, Artaza-Varasa T, Virseda-Berdices A, Fernández-Rodríguez A, Mendoza PM, Jiménez-Sousa MÁ, Resino S. MTHFR rs1801133 Polymorphism Is Associated With Liver Fibrosis Progression in Chronic Hepatitis C: A Retrospective Study. Front Med (Lausanne) 2020;7:582666. [PMID: 33304912 DOI: 10.3389/fmed.2020.582666] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Akar T. Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C? Rev Assoc Med Bras (1992) 2018;64:224-9. [PMID: 29641775 DOI: 10.1590/1806-9282.64.03.224] [Reference Citation Analysis]